CERO THERAPEUTICS HOLDINGS, INC. (CERO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US71902K4022
CERO THERAPEUTICS HOLDINGS, INC. financials
| Fiscal year | 2025 |
|---|---|
| EBIT | -19.92 m USD |
| Net income | -19.92 m USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
More stocks
- Cuentas Inc. (CUEN)
- Mosaic ImmunoEngineering Inc. (CPMV)
- Cheer Holding, Inc. (CHR)
- House of Doge Inc. (HODO)
- REGIONAL HEALTH PROPERTIES, INC (RHEPA)
- GROOVE BOTANICALS INC. (GRVE)
- Regenerative Medical Technology Group Inc. (RMTG)
- Webstar Technology Group Inc. (WBSR)
- Edgemode, Inc. (EDGM)
- Accredited Solutions, Inc. (ASII)
- Paion AG (PA8.F)
- Goliath Film & Media Holdings (GFMH)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.